Oncolytic herpes simplex virus (HSV)-1 g 1 34.5-deletion mutants (Dg 1 34.5 HSV) are promising agents for tumor therapy. The attenuating mutation renders the virus aneurovirulent but also limits late viral protein synthesis and efficient replication in many tumors. We tested whether one function of g 1 34.5 gene, which mediates late viral protein synthesis through host protein kinase R (PKR) antiviral response evasion, could be restored, without restoring the neurovirulence. We have previously reported the construction of two chimeric Dg 1 34.5 HSV vectors (chimeric HSV), C130 and C134, which express the human cytomegalovirus (HCMV) PKR-evasion genes TRS1 and IRS1, respectively. We now demonstrate the following. The HCMV/HSV-1 chimeric viruses (i) maintain late viral protein synthesis in the human malignant glioma cells tested (D54-MG, U87-MG and U251-MG); (ii) replicate to higher titers than Dg 1 34.5 HSV in malignant glioma cells in vitro and in vivo; (iii) are aneurovirulent; and (iv) are superior to other Dg 1 34.5 HSV with both improved reduction of tumor volumes in vivo, and improved survival in two experimental murine brain tumor models. These findings demonstrate that transfer of HCMV IRS1 or TRS1 gene into Dg 1 34.5 HSV significantly improves replication in malignant gliomas without restoring wild-type neurovirulence, resulting in enhanced tumor reduction and prolonged survival.
Introduction
Glioblastoma multiforme (GBM), the most common primary brain tumor, is one of the most fatal cancers due to the lack of efficacy of traditional therapies including surgery, chemotherapy and radiotherapy. 1 Median life expectancy for patients diagnosed with GBM is 12-15 months, and less than 5% survive to 5 years past the date of diagnosis. 2 One promising alternative treatment modality is the use of herpes simplex virus-1 (HSV-1) vectors with deletions in the g 1 34.5 gene. These engineered mutants are conditionally replication-competent vectors that selectively retain their oncolytic potential against glioma cells. The HSV-1 g 1 34.5 gene is the principal viral defense against an innate host antiviral response and encodes at least two independent functions. The carboxyl-terminal domain of the g 1 34.5 gene product encodes a function that maintains late viral protein synthesis in infected cells. 3 HSV-1 produces complementary mRNA transcripts in the infected cell that anneal and form double-stranded RNA (dsRNA). A host kinase, protein kinase R (PKR), binds dsRNA, activates and selectively phosphorylates the a subunit of eukaryotic initiation factor (eIF-2a), thereby inhibiting protein translation in the infected cell. The HSV-1 g 1 34.5 protein (ICP34.5) overcomes this PKR-mediated host protein shutoff by binding and recruiting a host phosphatase that specifically dephosphorylates eIF-2a, allowing continued viral protein synthesis in the infected cell. 4 Recombinant viruses lacking the g 1 34.5 gene (Dg 1 34.5 ) are incapable of maintaining unphosphorylated eIF-2a and therefore unable to maintain protein synthesis. 5, 6 Cessation of protein synthesis occurs at the onset of viral DNA synthesis late in infection (B6-8 h postinfection (h.p.i.)). 5, 6 Consequently, Dg 1 34.5 HSV replicate inefficiently and produce fewer progeny virions in cells with intact PKR pathways. 6, 7 A second function encoded by the g 1 34.5 gene permits efficient viral replication in postmitotic neuronal cells, conferring a neurovirulent phenotype to HSV-1. [8] [9] [10] [11] Previous studies have shown this function to be independent of the protein shutoff phenotype. 7, 12, 13 These Dg 1 34.5 HSV are incapable of efficient replication after direct inoculation in the central nervous system (CNS) and do not produce encephalitis. 8, 9, 14, 15 As such, Dg 1 34.5 HSV vectors have been developed as antitumor agents for CNS-based malignancies. 14, 15 A theoretical limitation of Dg 1 34.5 HSV is that protein synthesis and replication are limited, reducing viral spread and tumor lysis. To counter this, investigators have explored ways to limit wild-type viral replication only to the tumor cells through conditional expression of the g 1 34.5 neurovirulence gene through tumor-specific promoters or by limiting viral entry through tumorspecific antigens. 16, 17 We sought a different approach to restore late viral protein synthesis and improve Dg 1 34.5 replication in tumors without re-establishing viral neurovirulence. Previous studies demonstrated that Dg 1 34.5 recombinants encoding a PKR-evasion gene (TRS1 or IRS1) from a related herpesvirus, human cytomegalovirus (HCMV), exhibit wild-type protein synthesis phenotype. 18 We hypothesized that the IRS1 or TRS1 gene may selectively complement a Dg 1 34.5 HSV by restoring one function of the g 1 34.5 gene, wild-type protein synthesis, without restoring the other function, neurovirulence. The data in this report demonstrate that in the human malignant glioma cells tested, the PKR antiviral response is intact and that Dg 1 34.5 recombinants trigger the protein shutoff response. The HCMV/HSV-1 chimeric recombinants exhibited restored late viral protein synthesis, consistent with past studies in human foreskin fibroblasts, 18 replicated similar to wild-type virus in infected malignant glioma cells, but did not exhibit wild-type neurovirulence. In addition, the antitumor effects of the chimeric recombinants were superior to the parent, Dg 1 34.5 HSV. Imaging studies demonstrate that the chimeric HSV reduced tumor burden in vivo and improved survival in two experimental murine brain tumor models: a xenograft model of human glioma and a syngeneic murine neuroblastoma tumor model.
Results
The C130 and C134 chimeric viruses maintain late viral protein synthesis in infected human gliomas C101, C130 and C134 HSV recombinants have been described previously. 18 Their genetic organization is summarized as follows. All viruses lack both copies of the g 1 34.5 gene. C101 encodes the EGFP gene in the U L 3/ U L 4 intergenic region. In the chimeric HSV, this gene has been replaced with HCMV genes TRS1 (C130) or IRS1 (C134). Repair viruses C131 and C135 were constructed from C130 and C134, respectively, by replacing TRS1 or IRS1 with gene encoding enhanced green fluorescent protein (EGFP).
Alterations in PKR function in GBM tumor cells have been proposed as the basis of selective complementation and replication of Dg 1 34.5 HSV. Recent studies, however, indicate that PKR function is intact in some malignant glioma cell lines. 19, 20 Figure 1a, lanes 2, 4 and 6 ). The chimeric Dg 1 34.5 recombinants C130 and C134 behave similar to wild-type HSV-1 (F) and continue to synthesize viral proteins as demonstrated by radioactive methionine incorporation ( Figure 1a, lanes 1, 3 and 5) . Similar protein synthesis profiles are seen with infection of human malignant glioma cells U251-MG (Figure 1b ) and D54-MG (Figure 1c) . Inhibition of protein synthesis in Dg 1 34.5 HSV-infected cells is a function of PKR-mediated protein shutoff, as demonstrated by the detection of phosphorylated eIF-2a in the C101-, C131-and C135-infected cell samples ( Figure 1d, lanes 2, 4 and 6) . Conversely, phosphorylated eIF-2a is undetectable in cells infected with virus exhibiting wild-type protein synthesis. Immunoblotting studies using antibodies against total eIF-2a (Figure 1e) show that the presence of phosphorylated eIF-2a in lanes 2, 4 and 6 is specific to these virus-infected samples. Actin staining (Figure 2g ) shows equivalent protein loading. In cells infected with viruses that exhibit a wild-type protein synthesis phenotype, accumulation of viral proteins is anticipated. Immunostaining for the viral protein glycoprotein D (gD) demonstrates greater viral protein accumulation in the HSV-1 (F)-, C130-and C134-infected cell samples (Figure 1f ). These studies were repeated in both D54-MG and U251-MG cell lines and showed that the chimeric HSV replicated similar to wild-type HSV. In the U251-MG cell line, the chimeric generate 2-3 log greater virus than the Dg 1 34.5 recombinant virus (similar to that shown in the U87-MG cells). In the D54-MG cells, the chimeric HSV and wild-type HSV again replicated better than Dg 1 34.5 virus producing 7-10 Â more virus (data not shown). These data indicate that evasion of PKRmediated protein shutoff by the chimeric recombinants is not limited to U87-MG cells. F  C134  C101  C130  C131  C135  C134  C101  C130  C131  C135  C134  C101  C130  C131  C135  HSV- F  C134  C101  C130  C131  C135  C134  C101  C130  C131  C135  C134  C101  C130  C131  C135  HSV-F  HSV-F  U87-MG  U251-MG  D54- Chimeric HCMV/HSV-1 oncolytic viruses AC Shah et al death occurring in the highest dosage group. In contrast, C130 was more virulent than C101 (LD 50 6.8 Â 10 5 PFU) but is substantially less virulent than wild-type HSV-1(F) (nearly 4 log lower). These results show that insertion of either the HCMV IRS1 or TRS1 genes into a Dg 1 34.5 recombinant does not restore wild-type neurovirulence; however, the TRS1-expressing virus (C130) is more virulent than the parent virus (C101) or the IRS1-expressing (C134) chimeric virus. Taken together, these data indicate that while the TRS1 and IRS1 genes complement one function of the g 1 34.5 gene (late viral protein synthesis) leading to improved viral replication in tumors, they do not complement the other g 1 34.5 function (wild-type neurovirulence). These data are consistent with past studies that demonstrate that restoration of late viral protein synthesis function of g 1 34.5 gene does not restore wild-type neurovirulence. 7, 12, 13 Replication in the non-malignant murine CNS Although the LD 50 studies indicated that the chimeric HSV were as safe as Dg 1 34.5 used in prior clinical trials, we next sought to identify if there was subclinical replication of chimeric HSV in nonmalignant cells. To investigate this possibility, we performed in vivo virus recovery studies in chimeric HSV-and Dg 1 34.5-recombinant-infected animals. Cohorts of CBA/J mice were injected with equivalent amounts of the most neurovirulent chimeric HSV recombinant (C130) or with the Dg 1 34.5 parent virus C101. On days 2, 4, 6 and 8 postinfection, animals were killed from each cohort and the recovered virus measured from the recovered and homogenized brains using limiting plaque dilution. The results show that the chimeric HSV recombinant replicates similar to the Dg 1 34.5 recombinant C101 in the nonmalignant CNS (Figure 3 ). Neither the C130 or C101 recombinant is recoverable beyond day 4 post-infection in the nontumor-bearing mice and there is no statistical difference in virus recovery between the C130-and C101-infected animals on days 2 or 4 post-infection.
Treatment with chimeric HSV reduces tumor volume in SCID-mice bearing human glioma tumors
We hypothesized that the chimeric HSV, owing to their near wild-type replication in tumor and Dg 1 34.5 neurovirulence profile, would demonstrate enhanced antitumor activity and subsequent reduction of tumor burden versus Dg 1 34.5 HSV, but remain safe for intracranial injection. Human U251-glioma cells stably transfected with the firefly luciferase gene (U251-ffluc) were intracranially injected in severe combined immunodeficient (SCID) mice as before, and treated 1 week later with equivalent doses (2 Â 10 5 ) of Dg 1 34.5 (R3616) or chimeric HSV (C130). At weekly intervals after therapy, mice were administered beetle luciferin and the photonic activity recorded and quantified by charge-coupled device (CCD) Xenogen IVIS (Hopkinton, MA, USA). The luciferase enzyme is not present in native animal cells, and has a limited half-life at 371C of about 2 h. Thus, light emissions are limited to viable, metabolically active tumor cells. Differences in photonic activity between paired groups were calculated using the Mann-Whitney rank sum test. As shown in Figure 4 , the chimeric HSV C130-treated animals exhibited lower light emission than the saline (day 21 P ¼ 0.0007; day 28 P ¼ 0.008) or Dg 1 34.5 (day 21 P ¼ 0.0205; day 28 P ¼ 0.0014)-treated animals, indicative of a smaller viable tumor burden.
Treatment with C130 and C134 increases survival of SCID mice bearing U87-MG brain tumors
We next tested whether the enhanced reduction in tumor burden mediated by chimeric HSV therapy also translated to improved survival of tumor-bearing mice, as compared to therapy with Dg 1 34.5 HSV. For these studies, U87-MG xenografts were established in the brains of SCID mice as before. Seven days after tumor induction, mice were randomized into different cohorts of viruses and doses. In the first experiment, two C130 dose cohorts (5 Â 10 4 and 5 Â 10 5 PFU dose), as determined from the neurovirulence studies, were tested and compared with matching doses of C134. In a second experiment, equivalent doses of C130 and C134 (5 Â 10 5 PFU dose) and a higher C134 (5 Â 10 6 PFU dose) cohort were tested. Controls for each experiment included a vehicle (saline) treatment group and two dose cohorts of C101 (the Dg 1 34.5 parent virus used to construct the chimeric HSV): 5 Â 10 5 PFU for dose-matched comparison with C130 and C134, and 1 Â 10 7 PFU, the usual therapeutic dose for Dg 1 34.5 HSV-based vectors in murine models. Representative Kaplan-Meier survival graphs of equivalent- (Figure 5a ) and maximum administered dose ( Figure  5b ) are shown for the individual studies. 5 PFU, 4135 days (P ¼ 0.0166)). A similar trend was also seen with the C134 chimeric HSV but failed to achieve statistical significance (C101 1 Â 10 7 PFU ¼ 41.5 days vs C134 5 Â 10 5 PFU ¼ 4135 days (P ¼ 0.0938) (Figure 5a) ). To verify that the trend observed with the C134 chimeric HSV was real, the survival study was repeated using greater animal numbers to increase the statistical power. The results confirmed the initial study and showed that 5 Â These studies demonstrate that at a 20fold lower dose, the chimeric HSV vectors C130 and C134 significantly improved survival of U87 tumor-bearing SCID mice compared to treatment with Dg 1 34.5 parent virus C101. There was also a trend toward improved survival at a 200-fold dose reduction for the C130 recombinant in this study (P ¼ 0.0652).
Viral Recovery non-malignant CNS

Treatment with C130 and C134 improves survival in a syngeneic neuroblastoma brain tumor model
To determine whether this antitumor benefit would be translatable to different brain tumor types in different in situ environments, we examined viral oncolytic activity in a model of neuroblastoma immunocompetent mice. Neuro-2a is a murine neuroblastoma syngeneic to A/J strain mice that provided a stringent test for chimeric HSV oncolytic activity because Neuro-2a cells do not support efficient HSV infection and elicit no discernible antitumor immune response. [21] [22] [23] [24] [25] [26] Similar to our findings in the xenograft model, therapy with C130 or C134 chimeric HSV significantly improved survival in this rapidly fatal, syngeneic brain tumor model versus therapy with Dg 1 34.5 HSV (Table 2, C101 vs C130 P ¼ 0.0045; vs C134 P ¼ 0.0039).
Discussion
Ideally, replication-competent viruses will encompass certain characteristics essential for use in glioma therapy, including (i) a high level of discrimination between neoplastic cells and normal tissue, particularly neurons, (ii) minimal toxicity, (iii) a rapid proliferation and oncolysis rate to combat rapidly proliferating glioma cells and (iv) the ability to reach invasive tumor cells distant from the tumor mass. The Dg 1 34.5 HSV-1 vectors have consistently demonstrated antiglioma effects, while remaining aneurovirulent. 8, 12 Additionally, the safety of these viruses has been validated in clinical trials. 14, 15 However, Dg 1 34.5 mutants replicate poorly, resulting in incomplete tumor lysis in both experimental murine glioma models and HSV-treated patient tumor specimens. 27, 28 We hypothesized that transfer of the HCMV PKR evasion genes TRS1 (C130) or IRS1 (C134) gene to a Dg 1 34.5 HSV would improve viral replication and antiglioma activity.
In the human malignant gliomas tested, the PKRmediated antiviral response was intact and restricted ) would be 0.0069. Rather than combining the two survival studies as is commonly done, we used a more rigorous statistical analysis by evaluating each of the survival studies independently.
Deletion of g 1 34.5 renders HSV-1 functionally aneurovirulent and safe to inject intracranially because it can no longer replicate efficiently in post-mitotic cells such as neurons. 8, 9 However, this genetic modification has also been associated with a decrease in viral replication, even in permissive cell lines. 29 The HCMV TRS1 or IRS1 genes, while improving late viral protein synthesis, did not restore wild-type neurovirulence. The C134 (IRS1-expressing) recombinant had an identical safety profile as the Dg 1 34.5 parent virus C101 (LD 50 41 Â 10 7 ). Although the TRS1-expressing C130 was more neurovirulent than the C134 or C101, its LD 50 was 4 log lower than wild-type HSV-1(F) and it replicated similar to the aneurovirulent Dg 1 34.5 parent virus in the CNS. These results demonstrate the following points. First, whereas expression of the HCMV IRS1 or TRS1 genes by Dg 1 34.5 HSV-1 can restore one function of g 1 34.5 (wild-type Chimeric HCMV/HSV-1 oncolytic viruses AC Shah et al protein synthesis and replication in infected tumor cells), this genetic insertion does not restore another 'wild-type neurovirulence). Second, the HCMV TRS1 and IRS1 genes appear interchangeable with respect to protein synthesis function, replication and antiglioma efficacy, independent of their neurovirulence profiles. Third, the difference in neurovirulence does not appear to be a function of unrestrained C130 chimeric HSV replication in the CNS. The C130 and C101 recombinants have similar replication profiles in the nonmalignant CNS. At this time, it is not known if the chimeric HSV-and Dg 1 34.5-infected cells undergo different cell fates related to differences in PKR activation in the C101-, C130-or C134-infected post-mitotic cells CNS cells or whether neurovirulence is a function of additional functions encoded by the TRS1 gene or differences in the inflammatory response elicited by the viruses.
Owing to its high level of efficacy and low neurovirulence profile, C134 demonstrates the most advantageous therapeutic ratio, a critical determinant for its utility as an oncolytic vector for treatment of patients with cancer. C130, although more neurovirulent than C101, displays a safety profile similar to HSV1716, one Dg 1 34.5 HSV used in phase I clinical trials. 15, 30 HSV/HCMV chimeric viruses replicate efficiently and are more effective at lower doses than Dg 1 34.5 HSV, thus facilitating production and reducing the expense of manufacturing clinical grade material. Furthermore, in vitro plaque reduction assays demonstrated the chimeric HSV remains susceptible to acyclovir (data not shown). As demonstrated by their neurotoxicity profiles, unrestrained infections are unlikely, but sensitivity to antiviral agents offers a distinct advantage to HSV-based antitumor therapies compared to other viral-based strategies. Further characterization of both viruses will be required before either is advanced into the clinical arena.
The enhanced antitumor efficacy of the chimeric HSV, even at low doses, over that of C101 suggests improved intratumoral replication is one of the major mechanisms responsible for the improvement in survival of tumorbearing mice. However, additional antitumor mechanisms cannot be excluded. The TRS1 and IRS1 proteins could elicit a more robust immune response in the syngeneic Neuro-2a model that improves antitumor activity. A previous report indicates that these HCMV proteins are highly immunogenic when expressed in the context of HCMV infection; it is not known whether they enhance the immune response in the context of Dg 1 34.5 infection. 31 Chimeric HSV replication, TRS1/IRS1 exposure and tumor cell oncolysis may facilitate tumortargeted adaptive immune responses after subsequent exposure to tumor antigens. 32 It has also been proposed that antiviral immune responses are responsible for limiting the full potential of viral gene therapy agents, including HSV-1 vectors. 33 Thus, TRS1 and IRS1 expression from Dg 1 34.5 HSV-1 may permit more efficient tumor cell destruction before effective antiviral immune responses are generated. Involvement of host immune responses in the antitumor benefits seen here is currently being examined.
Several methods have been explored to improve Dg 1 34.5 replication and antitumor activity, including conditional expression of the principal HSV neurovirulence gene, g 1 34.5, using tumor-specific promoters or limiting wild-type virus entry by tumor-specific receptors. This approach has been shown to be effective in experimental models but could be problematic for the following reasons. First, insertion of the principal neurovirulence gene of the virus, albeit under a tumorspecific promoter, introduces the possibility of mutations in that promoter and leaky expression of the gene. Second, conditional expression requires re-engineering for different tumor types, and selection of the conditional promoter requires prior molecular characterization of the tumor for an individual patient. Finally, GBMs are highly heterogenous, and although the conditional g 1 34.5-expressing viruses may replicate like wild-type virus in a complementing tumor cell, their principal advantage is lost in tumor clones lacking these promoter enhancers. By preferentially targeting tumor cells that express the promoter transcription factors, this could theoretically lead to clonal selection for enhancer-minus tumor cells in the individual patient. The chimeric HSV achieve this same beneficial function (late viral protein synthesis and improved replication in the tumor) without utilizing a specific enhancer or promoter because the HCMV genes do not encode the potentially harmful neurovirulence function encoded by the g 1 34.5 gene. These results are consistent with past studies showing that restoration of Dg 1 34.5 late viral protein synthesis does not resurrect wild-type neurovirulence. 12, 13 Serial passage of Dg 1 34.5 HSV in tumor cells in culture selects for mutations, which allow for improved late viral protein synthesis and viral replication in the tumor. 7, 13, 34 Reports indicate that one of these second site mutants (the aUS11 compensatory mutant) was aneurovirulent (LD 50 46 Â 10 5 ) and provided improved antitumor activity. 13 Thus far, the vector has been used in flank tumor models systems or for treatment of prostate tumors and no intracranial tumor studies have been published using it. 21, [35] [36] [37] The approach of generating novel antitumor viral vectors through the construction of chimeric viruses warrants continued investigation. Substitution of a heterologous rhinovirus IRES sequence has been used to reduce the virulence and improve the therapeutic ratio of an oncolytic poliovirus. [38] [39] [40] Here, we instead utilized HCMV genes expressed by a Dg 1 34.5 HSV-1 to produce a more robust vector that maintained the safety profile of the parent. We showed that incorporation of the HCMV TRS1 and IRS1 genes, which block the dsRNA-dependent PKR response pathway to prevent shutdown of protein synthesis, into attenuated but replication-competent HSV-1 vectors produced a virus with enhanced antitumor efficacy and improved survival in experimental murine brain tumor models. The chimeric HSV augment the potential of these vectors for use against many tumors that are able to limit oncolytic viral therapy by activation of the PKR-mediated antiviral response, permitting more robust and efficient destruction of tumor cells. Further enhancement of these promising new chimeric HSV vectors for glioma therapy might include the introduction of foreign therapeutic genes to elicit more potent antitumor responses.
Materials and methods
Cells and viruses
U87-MG, Neuro-2a and Vero cell lines were obtained from American Type Culture Collection (Manassas, VA, Chimeric HCMV/HSV-1 oncolytic viruses AC Shah et al USA). D54-MG and U251-MG cells were obtained from DD Bigner (Duke University, Durham, NC, USA). U251-ffluc cells were kind gift from Michael C Jensen (City of Hope, Duarte, CA, USA) and were derived from U251-MG cells stably transfected with the firefly luciferase gene. Cells were propagated in Dulbecco's modified Eagle's medium (DMEM) supplemented with 5% newborn calf serum (Vero) or DMEM/F12 50/50 + 7% fetal bovine serum (U87, D54, U251, U251-ffluc, Neuro-2a). HSV-1 (F) (provided by B Roizman, University of Chicago, Chicago, IL, USA) is the prototypical HSV-1. Construction of R3616 (provided by B Roizman, University of Chicago, Chicago, IL, USA), C101, C130, C131, C134 and C135 has been described previously. 6, 8, 18 In brief, the C130 and C134 chimeric HSV recombinants are derived from the Dg 1 34.5 recombinant C101 and contain the HCMV TRS1 (C130) and IRS1 (C134) gene under control of an HCMV immediate early promoter. 18 The recombinant viruses C131 and C135 are repair viruses that, based on DNA hybridization studies, are predicted to be genetically identical to C101. 18 
Protein shutoff assay
Protein pulse-labeling experiments for virus-infected cells were performed as described previously using L-[ 35 S]methionine (Amersham Bioscience, Piscataway, NJ, USA). 18 Briefly, cells were infected with a high multiplicity of virus (10 PFU virus/cell) and radiolabeled for 1 h at 15 h post-infection.
Immunostaining
Equivalent protein mass (10 mg) from each infected cell lysate was loaded on 12% SDS-polyacrylamide gels, electrophoretically separated, transferred to nitrocellulose, and immunoblotting performed as previously described. 41 Antibodies used were rabbit anti-phosphorylated-eIF-2a (P-serine-51) (44-728 Biosource International; Camarillo, CA, USA), mouse monoclonal total eIF-2a (AHO0802 Biosource International; Camarillo, CA, USA), and mouse monoclonal anti-HSV gD (Advanced Biotechnologies; Columbia, MD, USA).
Multistep replication assays
Quadruple replicates of U87-MG, D54-MG and U251-MG cells were infected in parallel (multiplicity of infection (MOI) ¼ 0.1) with either wild type, C101, C130, C131, C134 or C135. Infected cell culture samples were subjected to three freeze-thaw and sonication cycles before quantifying virus by limiting dilution assay and plaque formation in Vero cells as described previously. 42 Each experiment was repeated at least once. Average recovered virus and standard deviation were calculated for each virus and time point tested.
In vivo virus recovery
In vivo viral recovery was measured by limiting dilution assay and by Taqman quantitative PCR. For the tumor recovery studies, U87-MG tumors were induced in SCID mice (as described above in the survival studies) and treated with equivalent doses (5 Â 10 5 PFU) of C101, C130 or C134 recombinant virus. On days 1, 2, 4 and 8 post-inoculation, three animals from each of the treatment cohorts were killed, their brains recovered, weighed, freeze-thawed, mechanically disrupted by homogenization and the samples were sonicated before quantifying the recovered virus by limiting dilution plaque assay or by Taqman quantitative PCR after DNA extraction using a Qiagen biorobot and Qiagen EZ1 tissue kit. Average recovered virus and standard deviation were calculated for each virus and time point tested. A similar method was used for the in vivo recovery studies from non-malignant CNS. Cohorts of 5-week-old CBA/J mice were injected with equivalent doses (5 Â 10 5 PFU) of C130 or C101. On days 2, 4, 6 and 8, animals were killed, brains were recovered and the infectious virus measured using limiting dilution plaque assay.
Neurovirulence studies
Female 5-week-old CBA/J strain mice (National Cancer Institute (NCI)) were stereotactically injected intracerebrally with graded doses of viruses via 10 ml PBS. Injections were performed as described previously. 7 HSV-1 (F) was used as positive control. Mice were, assessed daily, deaths noted up to 30 days, and LD 50 calculated based on Spearman-Karber statistical method.
For each of the viruses tested (C130, C134, C131 and C101), groups of 25 mice were divided into five cohorts (five mice/cohort/dose) and were inoculated with graded U87-MG cells were stereotactically injected intracerebrally into SCID mice (in 5 ml 5% methylcellulose in DMEM/F12) and treated after 7 days with virus (in 10 ml PBS vehicle) as described previously. 43, 44 Neuro2a cells (2 Â 10 4 ) were implanted into syngeneic A/J strain mice, and virus treatments administered after 5 days. Mice were assessed daily and moribund mice killed and date recorded. Survival curves determined using Kaplan-Meier analysis and median survivals and 95% confidence intervals calculated. 45, 46 Log-rank test was applied to compare survival between groups. The significance level was adjusted for multiple comparison. 45, 46 Studies were repeated twice to ensure biologic validity. In the initial experiment, eight animals/cohort were used for virus treatment and seven animals were used for saline treatment group. For the repeat experiment, 12 animals were used for each virus treatment cohort and compared with seven animals receiving saline therapy. Although the first experiment had no censored events, three deaths in the second experiment were censored. The three censored animals showed signs of inner ear disturbance (torticolis, rolling behavior) and were from different groups. The animals showed none of the weight loss or loss of grooming characteristic of tumor-related deaths yet their killing was mandated by UAB veterinary staff. Statistical analysis was performed on both censored and uncensored data and the deaths had no effect upon significance except for the C134 5 Â 10 5 dose when compared with the C101 1 Â 10 7 PFU
Chimeric HCMV/HSV-1 oncolytic viruses AC Shah et al group (P ¼ 0.04 with censored data vs P ¼ 0.09 without censored data).
IVIS measurement of glioma volume
U251-ffluc tumor cells (1 Â 10 6 cells) were xenografted in SCID mice similar to that described for the U87-MG survival studies. Cohorts of animals (10 animals/cohort) were then individually inoculated with saline or equivalent doses (2 Â 10 5 PFU) of either a Dg 1 34.5 virus (R3616) or chimeric HSV (C130). Intracranial tumor volumes were then measured by digitally capturing and quantifying photonic activity from the luciferase-expressing tumors following intraperitoneal beetle luciferin (2.5 mg/mouse) administration using a Xenogen CCD In Vivo Imaging System (IVIS). Differences in photonic activity between paired groups were calculated using the Mann-Whitney rank sum test from surviving members of the treatment groups.
